StreetAlpha.app
Home › Stocks › ALKS

Alkermes plc. (ALKS)

Healthcare
$45.45
▼ −2.32%
LAST CLOSE · NOV 17

Alkermes makes prescription medicines, including LUMRYZ and LYBALVI, sold to patients through physicians and healthcare payers. It last closed at $45.45 on Nov 17, down 2.32% on the day. The average 12-month price target from 5 analysts is $57.20 (+25.9% from the last close), with a high of $68.00 and a low of $50.00. Analyst consensus is Buy, based on the latest ratings from 5 firms (3 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in ALKS, 0% of them bullish and 100% bearish. In the past 30 days there were 3 dark pool prints totaling $11.7M, the largest $9.3M.

AI Auto Pilots
Is ALKS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.8B
+15.3% vs a year ago
Net income
−$351K
−100.1% vs a year ago
EPS (diluted)
−$0.01
−100.5% vs a year ago
Free cash flow
$227.4M
13.0% margin
Valuation
Market cap
$7.6B
168.0M shares
P/E
–
No P/E while losing money
Price to sales
4.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$631.3M
At Sep 30
Debt
$1.5B
At Sep 30
Shareholder equity
$1.9B
Shares outstanding
168.0M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.2B$1.2BFY2021FY2022: $1.1B$1.1BFY2022FY2023: $1.7B$1.7BFY2023FY2024: $1.6B$1.6BFY2024FY2025: $1.5B$1.5BFY2025

From ALKS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
5firms
3 Buy2 Hold0 Sell
Each firm's latest rating on ALKS in the past 90 days
Average 12-month target
$57.20
▲ 25.9% upside

Based on 5 analysts who set a price target on ALKS in the past 90 days. The average target is $57.20, with a high of $68.00 and a low of $50.00, compared with the last close of $45.45.

Low $50.00Avg $57.20High $68.00
Blue marker: last close $45.45
Highest target$68.00
Average target$57.20
Lowest target$50.00
Latest rating changes
RBC CapitalTarget raised
Nov 4Buy$56 → $57
Wells FargoTarget raised
Nov 4Buy$65 → $68
HC Wainwright & Co.Target raised
Nov 4Hold$37 → $50
Goldman SachsReinstated
Sep 24Hold$50
BairdTarget raised
Sep 22Buy$58 → $61
DateFirmActionRatingPrice target
Nov 4RBC CapitalTarget raisedBuy$56 → $57
Nov 4Wells FargoTarget raisedBuy$65 → $68
Nov 4HC Wainwright & Co.Target raisedHold$37 → $50
Sep 24Goldman SachsReinstatedHold$50
Sep 22BairdTarget raisedBuy$58 → $61
Loading…

Technical Analysis

ALKS · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 9% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 52). The nearest support is the Pivot S1 at $44.82, and the nearest resistance the 20 day average at $45.47.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNormal
VolatilityHigh, 3.7%/day
Key levels
$55.6752 week high+22.5%
$47.03100 day average+3.5%
$46.36Pivot R1+2.0%
$45.76Swing high (Jun 11)+0.7%
$45.73Pivot+0.6%
$45.4720 day average+0.0%
$45.45Last close
$44.82Pivot S1−1.4%
$44.63Swing low (Sep 8)−1.8%
$43.6850 day average−3.9%
$41.24200 day average−9.3%
$27.0052 week low−40.6%
Indicators
RSI (14)52.08Middle of its rangeNeutral
MACD0.89Above its signal lineBullish
Stochastic56.7Middle of its rangeNeutral
ADX (14)20.1Weak trend
Williams %R-67.3Oversold below −80, overbought above −20Neutral
CCI (20)19.3Oversold below −100, overbought above 100Neutral
Rate of change−0.5%Change over 10 sessionsBearish
ATR (14)$1.68Typical daily range, 3.7% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Above
What happened before, for ALKS

What happened before

See how ALKS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ALKS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ALKS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
0
0%
Bearish
2
100%
Date span
Oct 2 – Nov 17
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$11.7M
Largest print
$9.3M
Loading…

ALKS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●205 buying vs 188 selling
  • ▼Held by funds -1.8 pts
  • ▼Funds holding -12
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding415427−2.8%
In funds' top 10911−18.2%
Held by funds104.2%106.0%−1.8 pts
New / increased48 / 15787 / 137−8.5%
Reduced / sold out129 / 59137 / 52−0.5%
Put/call ratio0.510.03+1774.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALKS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALKS is in one of them and how their past ALKS trades turned out.

ALKS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALKS in an article yet. Here's the latest on the wider market.

ALKS Congress Trades

All congress trades →
Trades, 12 months
4
Buys
2
50%
Sells
2
50%
People
2
Last filed Oct 12
Who traded ALKS · since 2026
Latest 4 filings
$1K – $15KTraded Sep 29, 2026Filed Oct 12, 2026
$50K – $100KTraded Jul 29, 2026Filed Sep 22, 2026
$15K – $50KTraded Jul 30, 2026Filed Sep 4, 2026
$1K – $15KTraded May 15, 2026Filed Jul 1, 2026
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KSep 29, 2026Oct 12, 202613 d
Donald J TrumpExecutive branchSell$50K – $100KJul 29, 2026Sep 22, 202655 d
Gilbert CisnerosD · CABuy$15K – $50KJul 30, 2026Sep 4, 202636 d
Donald J TrumpExecutive branchSell$1K – $15KMay 15, 2026Jul 1, 202647 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Alkermes

Alkermes is a pharmaceutical company based in Dublin, Ireland, that makes prescription medicines. Its products include LUMRYZ and LYBALVI, which are sold in the U.S. and in markets outside the U.S. Physicians prescribe these products to patients, and sales depend on coverage and reimbursement from government programs, private insurers and pharmacy benefit managers. Pricing and coverage decisions by these payers affect how much revenue the company earns from its products.

Headquarters
Dublin 4, Ireland